Status:
COMPLETED
Safety of Catheter Lock With or Without Heparin in Implanted Central Venous Catheters
Lead Sponsor:
Universitaire Ziekenhuizen KU Leuven
Collaborating Sponsors:
Leuvens Kanker Instituut
Conditions:
Oncology, Medical
Hematologic Disease
Eligibility:
All Genders
1+ years
Phase:
PHASE4
Brief Summary
Long-term central venous access devices are considered as safe for the administration of medication as chemotherapy, but are also used for blood sampling. For years these catheters have been locked wi...
Eligibility Criteria
Inclusion
- Oncology and hematology patients
- Life expectancy of minimum of 180 days
Exclusion
- second or femoral long-term central venous access device
- known allergy to heparin (HIT)
- coagulation disorders(INR \>2, Blood platelets \> 1,000,000/mm3)
- therapeutic intravenous heparin administration
Key Trial Info
Start Date :
January 1 2009
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
June 1 2011
Estimated Enrollment :
1100 Patients enrolled
Trial Details
Trial ID
NCT00994136
Start Date
January 1 2009
End Date
June 1 2011
Last Update
June 9 2011
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Universitaire Ziekenhuizen Leuven
Leuven, Vlaams-Brabant, Belgium, 3000